Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.03 EUR
−73.15 M EUR
52.95 M EUR
134.99 M
About Ocular Therapeutix, Inc.
Sector
CEO
Pravin U. Dugel
Headquarters
Bedford
Website
Founded
2006
FIGI
BBG006WZLKR6
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0OT is 10.08 EUR — it has decreased by −0.30% in the past 24 hours. Watch OCULAR THERAPEUTIX INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange OCULAR THERAPEUTIX INC stocks are traded under the ticker 0OT.
0OT stock has fallen by −8.82% compared to the previous week, the month change is a 13.37% rise, over the last year OCULAR THERAPEUTIX INC has showed a 289.79% increase.
We've gathered analysts' opinions on OCULAR THERAPEUTIX INC future price: according to them, 0OT price has a max estimate of 20.35 EUR and a min estimate of 10.17 EUR. Watch 0OT chart and read a more detailed OCULAR THERAPEUTIX INC stock forecast: see what analysts think of OCULAR THERAPEUTIX INC and suggest that you do with its stocks.
0OT stock is 4.24% volatile and has beta coefficient of 2.01. Track OCULAR THERAPEUTIX INC stock price on the chart and check out the list of the most volatile stocks — is OCULAR THERAPEUTIX INC there?
Today OCULAR THERAPEUTIX INC has the market capitalization of 1.51 B, it has decreased by −6.25% over the last week.
Yes, you can track OCULAR THERAPEUTIX INC financials in yearly and quarterly reports right on TradingView.
OCULAR THERAPEUTIX INC is going to release the next earnings report on Nov 6, 2024. Keep track of upcoming events with our Earnings Calendar.
0OT earnings for the last quarter are −0.24 EUR per share, whereas the estimation was −0.21 EUR resulting in a −17.51% surprise. The estimated earnings for the next quarter are −0.22 EUR per share. See more details about OCULAR THERAPEUTIX INC earnings.
OCULAR THERAPEUTIX INC revenue for the last quarter amounts to 15.35 M EUR, despite the estimated figure of 14.80 M EUR. In the next quarter, revenue is expected to reach 15.38 M EUR.
0OT net income for the last quarter is −40.87 M EUR, while the quarter before that showed −60.10 M EUR of net income which accounts for 32.00% change. Track more OCULAR THERAPEUTIX INC financial stats to get the full picture.
No, 0OT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 6, 2024, the company has 267.00 employees. See our rating of the largest employees — is OCULAR THERAPEUTIX INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. OCULAR THERAPEUTIX INC EBITDA is −103.39 M EUR, and current EBITDA margin is −135.86%. See more stats in OCULAR THERAPEUTIX INC financial statements.
Like other stocks, 0OT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade OCULAR THERAPEUTIX INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So OCULAR THERAPEUTIX INC technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating OCULAR THERAPEUTIX INC stock shows the strong buy signal. See more of OCULAR THERAPEUTIX INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.